Skip to main contentAI and Advanced
/
PPLPHARMA · NSEBSE SENSEX74,379.62+0.06%BSE |
NIFTY 5023,283+0.28%NSE |
NIFTY BANK56,115.8-0.31%NSE |
NIFTY IT29,106.25+0.06%NSE |
NIFTY AUTO27,229.25+1.25%NSE |
NIFTY FMCG45,600.75+0.09%NSE |
NIFTY PHARMA26,569.8+1.62%NSE |
NIFTY 50022,664.8+0.59%NSE |
PP
NSE · Equity shares · Biotechnology & Drugs1.62 · 0.80%
Piramal Pharma PPLPHARMA
NSE:INR 203.99
BSE:INR 204.15
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for PPLPHARMA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 202.37
Day rangeINR 198.86 — INR 207.96
52-week rangeINR 132.3 — INR 231.93
Volume29.65 L
Market cap27,934.9
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)8,869.08
Net Income (INR Cr)-325.94
Rev Growth (5 Year %)24.72
EPS-1.22
Research path: Interpret Piramal Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
PPLPHARMAPiramal Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 17,965.04 | 15,677.59 | 15,311.81 |
| Accumulated Depreciation Total | -3,519.66 | -2,809.2 | -2,363.59 |
| Cash Equivalents | 225.03 | Not available | Not available |
| Other Liabilities Total | 250.56 | 224.27 | 200.22 |
| Accrued Expenses | 130.86 | 210.15 | 159.43 |
| Long Term Debt | 4,299.97 | 3,214.07 | 2,483.75 |
| Common Stock Total | 1,327.16 | 1,324.35 | 1,322.95 |
| Other Equity Total | 892.56 | 544.73 | 458.68 |
| Other Current Assets Total | 31.7 | 157.42 | 140.5 |
| Prepaid Expenses | 97.74 | 79.18 | 64.02 |
| Total Assets | 17,965.04 | 15,677.59 | 15,311.81 |
| Current Portof LT Debt/Capital Leases | 491.39 | 547.92 | 937.04 |
| Additional Paid-In Capital | 4,768.3 | 4,737.2 | 4,724.94 |
| Cash | 974.85 | 368.98 | 356.82 |
| Total Equity | 8,162.62 | 8,125.47 | 7,911.37 |
| Long Term Investments | 305 | 271.09 | 240.26 |
| Retained Earnings(Accumulated Deficit) | 1,174.6 | 1,519.19 | 1,404.8 |
| Total Common Shares Outstanding | 132.72 | 132.44 | 132.29 |
| Property/Plant/Equipment Total-Gross | 9,161.52 | 7,832.69 | 7,179.55 |
| Tangible Book Valueper Share Common Eq | 30.3 | 30.5 | 27.38 |
| Goodwill Net | 1,257.43 | 1,148.21 | 1,122.55 |
| Total Liabilities | 9,802.42 | 7,552.12 | 7,400.44 |
| Total Debt | 5,674.59 | 4,856.47 | 4,710.16 |
| Short Term Investments | 131.78 | 19.56 | 144.69 |
| Cashand Short Term Investments | 1,331.66 | 388.54 | 501.51 |
| Total Receivables Net | 2,478.98 | 2,718.35 | 2,462.03 |
| Notes Payable/Short Term Debt | 747.8 | 995.32 | 1,171.38 |
| Deferred Income Tax | 358.18 | 248.35 | 229.18 |
| Accounts Receivable-Trade Net | 2,212.03 | 2,376.84 | 2,135.56 |
| Property/Plant/Equipment Total-Net | 5,641.85 | 5,023.49 | 4,815.97 |
| Total Current Liabilities | 4,758.28 | 3,766.27 | 4,369.3 |
| Total Inventory | 3,251.58 | 2,453.5 | 2,296.41 |
| Accounts Payable | 2,479.11 | 1,533.77 | 1,538.37 |
| Other Currentliabilities Total | 909.12 | 479.11 | 563.08 |
| Total Long Term Debt | 4,435.4 | 3,313.23 | 2,601.74 |
| Intangibles Net | 2,884.47 | 2,938.63 | 3,167.21 |
| Other Long Term Assets Total | 552.21 | 413.83 | 407.33 |
| Note Receivable-Long Term | 132.42 | 85.35 | 94.02 |
| Total Current Assets | 7,191.66 | 5,796.99 | 5,464.47 |
| Capital Lease Obligations | 135.43 | 99.16 | 117.99 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %100.7
Margins
Operating Margin 12m-0.7
Operating Margin 5y Avg11.64
Net Profit Margin 12m-3.41
Net Profit Margin 5y-0.07
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio3.15
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk38.6
Analyst consensus
ConsensusStrong Buy
Consensus score1.44
Analyst opinions9
Strong Sell count0
Sell count0
Hold count0
Buy count4
Strong Buy count5
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 34.80%
- FII
- 12.51%
- MF
- 13.18%
- Other
- 39.51%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Stocks to buy or sell: Dharmesh Shah of ICICI Sec suggests buying Piramal Pharma on 20 JulyMarket news · 20 Jul 2026, 9:43 am
Indian stock indices faced losses on 20 July as HDFC Bank's disappointing earnings pressured the market. The BSE Sensex dropped 0.72%. Additionally, rising crude oil prices due to escalating Middle East tensions contributed to negative investor sentiment across sectors.
Stocks to buy or sell: Dharmesh Shah of ICICI Sec suggests buying Shriram Finance, Piramal Pharma shares on 6 JulyMarket news · 6 Jul 2026, 9:48 am
Indian benchmark indices, Sensex and Nifty 50, opened higher on July 6, driven by gains in private banking stocks following strong quarterly updates from HDFC Bank and Axis Bank. Market breadth was positive with 14 of the 16 major indices in the green.
Top Gainers & Losers on Mar 12: Piramal Pharma, Tejas Networks, Apollo Tyres, PG Electroplast among top losersMarket news · 12 Mar 2026, 3:40 pm
The Indian stock market extended its losses on March 12, with the Nifty 50 and Sensex down 1% and 1.08%. Tensions in the Middle East affected investor sentiment, particularly impacting auto stocks, while broader markets showed some positive movement.
Buy or sell: Vaishali Parekh recommends three stocks to buy today — 11 March 2026Market news · 11 Mar 2026, 5:13 am
Buy or sell stocks: Vaishali Parekh recommends three stocks to buy today — Piramal Pharma, Bharat Dynamics, and Oberoi Realty
Piramal Pharma moves SC against Gujarat pollution body's plant closure orderMarket news · 8 Feb 2026, 12:49 pm
Piramal Pharma's plea is slated to be heard on 9 February before a bench led by Chief Justice of India Surya Kant, along with Justices Joymalya Bagchi and N.V. Anjaria.
Piramal Pharma points to early recovery signs after seeing red in Q3Market news · 29 Jan 2026, 3:44 pm
The company posted its results for the third quarter of FY26 late on Wednesday evening, with its revenue dipping 3% year-on-year to ₹ 2,140 crore, and slipping to a loss of ₹ 136 crore from a net profit of ₹ 4 crore in Q3FY25. Its ebitda margin shrank from 16% in Q3FY25 to 11% this fiscal.
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- dividendRs.0.1400 per share(1.4%)Final Dividend
Rusaka Markets Community
Discussion and sentiment for Piramal Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United Kingdom/Europe, and North America. It has a commercial presence in over 100 countries. The Company operates under three business verticals: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a Complex Hospital Generics (CHG) business; and Piramal Consumer Healthcare business, selling over-the-counter products. PPS caters to both drug substances - Active Pharmaceutical Ingredients (APIs), and drug products (formulations). PCC's complex hospital product portfolio comprises hospital-focused products in the areas of inhalation anesthesia, intrathecal therapy, injectable anesthesia and pain management, and other generic and specialty products.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- PPLPHARMA
- BSE Code
- 543635
Questions
Stock FAQ
What is the symbol and ISIN of Piramal Pharma?
Piramal Pharma has the symbol PPLPHARMA and ISIN - INE0DK501011.
What is the current price of Piramal Pharma?
Piramal Pharma is currently trading at INR 203.99.
What are the year high and year low of Piramal Pharma?
Piramal Pharma has a year high of INR 231.93 and a year low of INR 132.30.
What is the market capitalization of Piramal Pharma?
Piramal Pharma has a market capitalization of INR 27,934.90 crore.
What is the P/E ratio of Piramal Pharma?
Piramal Pharma has a P/E ratio of NA.
What is the dividend yield of Piramal Pharma?
Piramal Pharma has a dividend yield of 0.00%.
How is the financial performance of Piramal Pharma based on revenue, net income, and EPS?
Piramal Pharma has revenue of INR 8,869.08 crore, net income of INR -325.94 crore, and EPS of INR -1.30.
What is the book value of Piramal Pharma?
Piramal Pharma has a book value of NA.
What is the debt-to-equity ratio of Piramal Pharma?
Piramal Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Piramal Pharma?
Piramal Pharma has a price-to-book ratio of NA and a price-to-sales ratio of 3.15.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.